Nom du produit:5-ThiazolecarboxaMide, 2-[(1R)-1-aMinoethyl]-N-[5-chloro-4-(trifluoroMethyl)-2-pyridinyl]-
IUPAC Name:2-[(1R)-1-aminoethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
- CAS:1095823-62-3
- Formule moléculaire:C12H10ClF3N4OS
- Pureté:95%+
- Numéro de catalogue:CM451125
- Poids moléculaire:350.74
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1095823-62-3
- Formule moléculaire:C12H10ClF3N4OS
- Point de fusion:-
- Code SMILES:C[C@@H](N)C1=NC=C(S1)C(=O)NC1=NC=C(Cl)C(=C1)C(F)(F)F
- Densité:
- Numéro de catalogue:CM451125
- Poids moléculaire:350.74
- Point d'ébullition:
- N° Mdl:MFCD22665902
- Stockage:
Category Infos
- Thiazoles
- Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Tovorafenib
- Tovorafenib is a highly selective, brain-penetrating pan-RAF kinase inhibitor designed to target key enzymes in the MAPK signaling pathway. Tovorafenib has been granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of pediatric patients with low-grade gliomas harboring RAF mutations. The hope is to bring this therapy soon to children in need of new treatment options.